The geneMAP™ FLT3 ITD/D835Y Mutation Detection Kit combines allele-specific PCR with fluorescence fragment analysis to offer superior analytical sensitivity and specificity in detecting the FLT3 gene mutations, specifically the D835Y mutation and Internal Tandem Duplication (ITD). These mutations are prevalent in 15-35% of adult acute myeloid leukemia (AML) cases and are associated with increased risk of treatment failure and poor prognosis. The kit, which is compatible with ABI 3100 series and 3500 sequencer instruments and CE-IVD certified, is designed for fast and easy use with multiplex real-time PCR technology, making it an essential tool in the routine clinical diagnosis and…
- Advanced Detection Methods: Utilizes a combination of allele-specific PCR and fluorescence fragment analysis for high sensitivity and specificity.
- Multiplex Real-time PCR Technology: Enables the simultaneous detection of FLT3-ITD and D835Y mutations, enhancing diagnostic efficiency.
- Instrument Compatibility: Specifically designed for compatibility with ABI 3100 series and 3500 sequencer instruments.
- CE-IVD Certification: Meets European standards for in vitro diagnostic medical devices, ensuring reliability and quality.
- Accurate Mutation Identification: Provides precise detection of critical FLT3 gene mutations, aiding in the accurate prognosis and diagnosis of AML.
- Rapid and User-Friendly: Simplified testing process allows for quick and efficient mutation screening, facilitating timely therapeutic decisions.
- Comprehensive Analysis: With the ability to detect both ITD and D835Y mutations, this kit offers a comprehensive approach to understanding the genetic landscape of AML patients.
- Diagnosis and Prognosis of AML: Essential for identifying FLT3-ITD and D835Y mutations in patients with acute myeloid leukemia, playing a vital role in assessing treatment response and overall prognosis.
- Guidance for Treatment Planning: Detection of these mutations at diagnosis assists in determining the optimal treatment strategy for AML patients, contributing to personalized medicine approaches.
- Mutation Coverage: Targets the FLT3-ITD and Tyrosine Kinase Domain (TDK) D835Y mutations, addressing significant genetic variations associated with AML.
- Technology: Employs allele-specific PCR and fluorescence fragment analysis for efficient and accurate mutation detection.
- Compatibility: Suitable for use with ABI 3100 series and 3500 sequencer instruments.
- Certification: Carries the CE-IVD mark, indicating compliance with EU regulations for in vitro diagnostic use.
Why Choose Clent
We strive to enable our customers to focus on the results of their work, rather than the tools they use. Need to speak with a member of our team? Get in touch today.